title: The cephalic and gastric phases of gastric secretion during H2-antagonist treatment.
abstract: The antisecretory effects of H2-receptor antagonists are limited by food ingestion. The contributions of the cephalic-vagal and gastrinergic mechanisms to this interaction were examined in two 14-hour randomized, cross-over studies in 24 healthy volunteers. In the first study, either ranitidine or placebo was administered IV by a pH-feedback-controlled infusion pump during fasting, modified sham feeding, or food ingestion. Sham feeding resulted in a well-defined and abrupt interaction with the antisecretory effect of ranitidine (lasting 2-3 hours), after which fasting pH levels were regained. The second study, with the same design, showed that gastrin release occurred during this cephalic-vagal phase but was not attenuated by the additional infusion of the anticholinergic pirenzepine. Following eating, intragastric acidity increased and remained elevated for more than 6 hours. This increase was accompanied by prolonged hypergastrinemia, which was not diminished by pirenzepine. Pirenzepine did, however, enhance the antisecretory effect of ranitidine after both sham feeding and food ingestion. The interaction of food or sham feeding with the antisecretory effect of H2 antagonists is a consistent phenomenon. In both the cephalic-vagal and the gastric phases of secretion, this interaction appears to be partially mediated by a noncholinergic release of gastrin.
authors.affiliation: Gastrointestinal Unit, Inselspital, University of Berne, Switzerland.
authors.forename: H S
authors.initials: HS
authors.lastname: Merki
authors.forename: C H
authors.initials: CH
authors.lastname: Wilder-Smith
authors.forename: R P
authors.initials: RP
authors.lastname: Walt
authors.forename: F
authors.initials: F
authors.lastname: Halter
mesh_terms: D000328:Adult; D005215:Fasting / Q000502:physiology; D005260:Female; D005502:Food; D005744:Gastric Acid / Q000378:metabolism*; D005755:Gastrins / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007260:Infusion Pumps; D008297:Male; D010890:Pirenzepine / Q000494:pharmacology; D011899:Ranitidine / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors; D014630:Vagus Nerve / Q000502:physiology
chemical_list: D005755:Gastrins; D010890:Pirenzepine; D011899:Ranitidine